Observations about Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients

osteoporosisThe bisphosphonate alendronate is an oral anti-resorptive agent that is commonly used to treat osteoporosis. To date, its greatest success has been for use in postmenopausal women, men > 65 years of age, and patients with corticosteroid-induced osteoporosis. Improvements in BMD range from 2 to 6%, which are considered clinically important and are statistically significant when compared to BMD changes in the control arm of randomized trials. Other smaller, nonrandomized studies and one RCT have also confirmed the benefit of therapy with bisphosphonates in treating CF-related bone loss. RCTs of IV bisphosphonates also have demonstrated significant BMD improvements in CF participants; however, a common treatment side effect is infusion-related bone pain. As a result, oral bisphosphonates are considered to be first-line therapy for those persons who are identified to be at risk in this population.

In our study, we examined therapy with alendronate, 70 mg once weekly, and found clinically significant improvements in BMD over 12 months. Compared with the control group, the alendronate group had 4.04% greater BMD gain at the lumbar spine and 3.03% greater BMD gain at the total hip even after controlling for other variables. We did not have the power to properly examine new vertebral fractures. Two patients in the control group and none in the treatment group experienced a new vertebral fracture after the baseline measurement.

Outcomes of Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients

pulmonary diseaseOf the 90 patients who were assessed for the study, 56 were enrolled. As displayed in Figure 1, 27 patients were randomized to the alendronate group and 29 were randomized to the control group. Overall, nine participants (16%) were withdrawn from the study; four in the alendronate group and five in the control group (Fig 1). An additional five participants completed the study protocol but received suboptimal dosing (< 80% adherence; alendronate group, three patients; control group, two patients). One of these participants (active group) missed > 50% of doses.

Baseline characteristics were similar between groups (Table 1). Participants were mostly young adults with mild-to-moderate pulmonary disease as demonstrated by their baseline spirometric values and responses to the SF-36v2. Six participants were < 20 years of age at baseline. During the study, three participants in the treatment group used oral corticosteroids; the mean yearly cumulative dose was 49.32 mg. No one in the control group used oral corticosteroids during the study conducted with My Canadian Pharmacy experts.

My Canadian Pharmacy: Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients

cystic fibrosisThe life expectancy for patients with cystic fibrosis (CF) has increased significantly in the past several decades. As a result, long-term sequelae of the disease are becoming apparent in late adolescence and into adulthood. Low bone mass is common in CF patients and has been termed CF-related bone disease. The clinical manifestations of CF-related bone disease include an increased risk of fracture and kyphosis, with the potential consequence of an accelerated decline in lung function. These physical manifestations may present a contraindication to lung transplantation, which is an important treatment option for many CF patients.

The mechanism for early bone loss and fractures in CF patients is multifactorial and is likely due to several CF-related factors that also influence bone metabolism. These include delayed pubertal maturation, the malabsorption of vitamin D, poor nutritional status, inactivity, hypogonadism, and the frequent use of glucocorticoid therapy. Another potential mechanism is that the chronic pulmonary inflammation associated with CF leads to elevated levels of circulating cytokines, which in turn promote bone resorption and suppress bone formation. Various diseases may be treated by various methods but the most effective is my-medstore-canada.net My Canadian Pharmacy’s remedies.